Panatus tab n / 20mg film about 10 pc

Description

Composition
Active substance:
1 tablet contains: butamirata citrate 20.00 mg.
Excipients:
Lactose monohydrate, povidone K-25, a dye quinoline yellow (E104), hypromellose 15000 mPa.s, talc, magnesium stearate, colloidal silicon dioxide shell Film: Hypromellose 6 mPa.s, titanium dioxide (E171), iron colorant oxide red (E172), iron colorant oxide yellow (E172), talc, propylene glycol.
Description:
Round, biconvex tablets with beveled film-coated yellow-brown color.
View of the fracture: Yellow rough mass of film-coated yellow-brown color.
Product form:
Tablets, film-coated, 20 mg.
10 tablets were placed in a blister made of PVC / Al foil (PVC / Al-foil).
1 blister pack placed in a carton together with instructions for use.
Contraindications
Increased sensitivity to the drug, pregnancy (I term), lactation, children under 6 years, lactase deficiency, lactose intolerance syndrome glucose-galactose malabsorption.
Carefully
Pregnancy (II-III trimesters).
Dosage
20 mg
Indications
Dry cough of any etiology, including whooping cough, cough suppressants in the preoperative and postoperative period in surgical interventions and bronchoscopy.
Interaction with other drugs
Any drug interactions are not described for butamirata.
Due to the fact that butamirata suppresses the cough reflex, avoid simultaneous use of expectorants to avoid accumulation of mucus in the airways.
In the period of the drug is not recommended Panatus forte use of ethanol as well as medicaments, CNS depressants (hypnotics, neuroleptics, tranquilizers, etc.).
Overdose
Symptoms: drowsiness, dizziness, nausea, vomiting, abdominal pain, diarrhea, irritability, impaired coordination of movements, lowering blood pressure.
Treatment: gastric lavage, activated charcoal designate, laxatives, as well as to take measures to maintain the function of the cardiovascular and respiratory systems. No antidote. Treatment is symptomatic.
pharmachologic effect
Pharmacological group:
Antitussive central action.
Pharmacodynamics:
Butamirata – active substance preparation Panatus forte, is a centrally acting antitussive agent unrelated to the opium alkaloids do not chemically or pharmacologically. Suppresses cough, having a direct effect on the cough center. It has a bronchodilator effect. It helps ease breathing, improving spirometry (reduces airway resistance) and blood oxygenation.
Pharmacokinetics:
Butamirata rapidly and completely absorbed by ingestion.
With repeated use butamirata its concentration in the blood plasma remains linear and accumulation was observed.
Hydrolysis butamirata initially to 2-phenylbutyric acid and dietilaminoetoksietanola starts in blood. These metabolites also possess antitussive activity. Butamirata and its metabolites have nearly maximum (about 95%) degree of binding to plasma proteins, which leads to their long half-life (T1 / 2) and a long antitussive effect. Metabolites derived primarily by the kidneys, and acidic metabolites largely associated with glucuronic acid. T1 / 2 is 6 hours.
Pregnancy and breast-feeding
No safety data Panatus use of the drug during pregnancy and it passes through the placental barrier. The drug is not recommended for use in the I trimester of pregnancy. In II and III trimester of pregnancy is possible to use the drug only after consulting your doctor. Given the lack of data on the allocation of butamirata in mother’s milk, the use of the drug Panatus fort during breastfeeding is not recommended.
Conditions of supply of pharmacies
Available without prescription.
side effects
Classification of the incidence of side effects of the World Health Organization (WHO): very common> 1/10, often by> 1/100 to 1/1000 to 1/10000 to 1/100000, including isolated reports.
On the part of the central nervous system (CNS): rare: drowsiness, dizziness.
From the digestive system: rare: nausea, vomiting, diarrhea.
For the skin: rare: rash.
Other: may develop allergic reactions.
special instructions
One tablet coated with a film coating comprising 314.90 mg of lactose. Each administration of a preparation in accordance with the instruction patient receives up to 629.8 mg of lactose. Panatus drug not used in patients with a deficiency of lactase, lactose deficiency, a syndrome of glucose-galactose malabsorption.
If after 5-7 days of drug Panatus cough does not stop, seek medical advice.
Panatus drug can cause drowsiness, so care must be taken when driving and complex technical devices, require high concentration and psychomotor speed reactions.
Storage conditions
At temperatures above 25 C, in the original package.
Keep out of the reach of children.
Dosing and Administration
Inside, the food.
Children 6 to 12 years: 1 tablet 2 times a day; children over 12 years: 1 tablet 3 times a day; adults: 2 tablets 2-3 times a day.
If cough persists for more than 5-7 days, you should consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist